Compare DexCom, Inc. (DXCM) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares Core S&P 500 ETF — how do they compare? DexCom, Inc. trades at $83.36 (market cap $31.86B), while iShares Core S&P 500 ETF trades at $782.1 (market cap $897.20B). The key difference: iShares Core S&P 500 ETF is far larger — about 28.2× DexCom, Inc.'s market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares Core S&P 500 ETF for 46 Days on average.
| DXCM | IVV | |
|---|---|---|
Market Cap | $31.86B | $897.20B |
Volume | 3,607,070 | 4,580,672 |
Sector | Health | Broad Market / Factor |
52-Week High | $92.34 | $782.58 |
52-Week Low | $54.84 | $634.93 |
Typical Hold Time | 62 Days | 46 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
IVV, tracking the S&P 500, trades at $779.68, down 0.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights mixed S&P 500 valuation signals, with earnings growth expected to slow in 2027 but historical seasonal patterns suggesting potential upside. The ETF's fundamentals reflect the index's aggregate metrics, with no company-specific financials reported.
Outlook remains cautiously optimistic given the bullish technical bias and index-level support, though risks include concentration in top holdings and macroeconomic headwinds. Investors gain diversified exposure to large-cap U.S. equities, but should monitor earnings trends and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
